/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

NEWAMSTERDAM PHARMA COMPANY NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$35.52 -0.0733(-7.33%) NAMS at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 34.6
Highest Today 37.65
Today’s Open 36.92
Prev. Close 38.33
52 Week High 42.00
52 Week Low 14.06
Day’s Range: Low 34.6 High 37.65
52-Week Range: Low 14.06 High 42.00
1 day return -
1 Week return -14.07
1 month return -2.84
3 month return +38.4
6 month return +83.26
1 year return +94.46
3 year return +323.38
5 year return -
10 year return -

Institutional Holdings

Bain Capital Life Sciences Investors, LLC 9.52

FCPM III SERVICES BV 9.44

RA Capital Management, LLC 9.00

American Funds SMALLCAP World A 7.45

Capital World Investors 7.45

Viking Global Investors LP 6.20

Deerfield Management Co 4.54

Wellington Management Company LLP 2.95

Adage Capital Partners Gp LLC 2.68

Jennison Associates LLC 2.62

Medicxi Ventures Management (Jersey) Ltd 2.55

Polar Capital Biotech S Inc 2.44

Polar Capital Holdings PLC 2.24

AllianceBernstein L.P. 2.07

Cormorant Asset Management, LLC 1.93

Vanguard Health Care Inv 1.91

Capital Research & Mgmt Co - Division 3 1.83

HHG PLC 1.74

FMR Inc 1.69

Woodline Partners LP 1.68

Pictet Asset Manangement SA 1.61

Maverick Capital Ltd 1.36

JPMorgan Chase & Co 1.30

Capital Group Global Equity Canada F 1.17

Pictet-Biotech P USD 0.87

JPMorgan Small Cap Growth A 0.73

Jennison Health Sciences Equity 0.69

PGIM Jennison Health Sciences Z 0.69

Jennison SMid Cap Core Equity 0.65

PGIM Jennison Small Company A 0.65

AB Small Cap Growth A 0.61

Pictet-Global Megatrend Sel I USD 0.61

Candriam Eqs L Biotech C USD Cap 0.60

American Funds New Economy A 0.60

Capital Group New Economy Comp 0.60

Fidelity Select Biotechnology 0.57

BNP Paribas Health Cr Innovtr Cl Cap 0.53

AB Discovery Growth A 0.48

MEDICAL BioHealth EUR Acc 0.44

American Century U.S. Small Cap Growth 0.40

Market Status

Strong Buy: 5

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4346.27 M

PB Ratio 6.4321

PE Ratio 0.0

Enterprise Value 3980.36 M

Total Assets 864.62 M

Volume 2178464

Company Financials

Annual Revenue FY24:45563000 45.6M, FY23:14090000 14.1M, FY22:97500000 97.5M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:45563000 45.6M, FY23:14045606 14.0M, FY22:97500000 97.5M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:null 0.0M, FY23:-176937000 -176.9M, FY22:-148884000 -148.9M, FY21:-28815000 -28.8M, FY20:-6093000 -6.1M

Quarterly Revenue Q3/2025:348000 0.3M, Q2/2025:19145000 19.1M, Q1/2025:2978000 3.0M, Q3/2024:29111000 29.1M, Q2/2024:2127446 2.1M

Quarterly Profit Q3/2025:348000 0.3M, Q2/2025:19145000 19.1M, Q1/2025:2978000 3.0M, Q3/2024:29111000 29.1M, Q2/2024:2109708 2.1M

Quarterly Net worth Q3/2025:-72005000 -72.0M, Q2/2025:-17364000 -17.4M, Q1/2025:-39527000 -39.5M, Q3/2024:-16647000 -16.6M, Q2/2024:-36413034 -36.4M

Fund house & investment objective

Company Information NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Organisation Biotechnology

Employees 68

Industry Biotechnology

CEO Dr. Michael Harvey Davidson FACC, Facp., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow